Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986416 with and without nivolumab in solid tumors
NL-OMON58729Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of AVID200 and nivolumab in Nonhematologic neoplasms (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Primary endpoint(s). Started Jul 2023; status: completed.
02
Drugs
AVID200nivolumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON58729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58729.